Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 上海莱士成立于1988年 注册地址为上海市奉贤区望园路2009号。公司注册资本6,645,480,758元人民币，2008年6月于深圳证券交易所上市，是集原料血浆采集、血液制品研发、生产、销售于一体的国内血液制品领先企业。 上海莱士整体规模为国内血液制品行业领先 是国内同行业中结构合理、产品种类齐全、血浆利用率较高的血液制品生产企业。公司秉承“安全、优质、高效”的质量方针，严格遵循《药品管理法》、《药品生产质量管理规范》、《中国药典》，并参考美国、欧洲的相关法律法规，建立完善的质量管理体系，主要产品包括：人血白蛋白、静注人免疫球蛋白（PH4）、人凝血因子Ⅷ、人纤维蛋白原、人凝血酶原复合物、人凝血酶、人纤维蛋白粘合剂等，是目前国内少数可以从血浆中提取六种组分的血液制品生产企业之一，是国内同行业中凝血因子类产品种类最为齐全的生产企业之一，也是国内少数能够出口血液制品的生产企业之一。 截止至2023年12月底，上海莱士共有上海、郑州、合肥、温州、南宁5个血液制品生产基地；公司及其下属子公司、孙公司拥有单采血浆站44家，分布于广西、湖南、海南、陕西、安徽、广东、内蒙、浙江、湖北、江西、山东11个省（自治区），浆站数量、分布区域及全年采浆量均位居行业前列。 上海莱士是“上海市外商投资先进技术企业”，上海市科学技术委员会认定的“高新技术企业”，“院士专家工作站”。通过三十多年的深耕细作，上海莱士产品在行业内树立起了安全、优质的品牌形象，产品质量获得国内消费者的信赖以及国际市场的认可。曾连续多年获得“上海市著名商标”、“上海名牌”称号，并多次获得福布斯“最具创新力企业”，成为业界较有影响力的企业。 长期以来，上海莱士产品在行业内树立起了安全、优质的品牌形象，产品质量获得国内消费者的信赖及国际市场的认可，始终坚持“安全、优质、高效”的质量方针，践行“上海莱士 健康卫士”的品牌承诺，为患者采更多的浆，做更多的药，做更好的药，创更新的药，泽福社会。
Main Business 血液制品的研发、生产和销售。
Legal Representative 谭丽霞
Top Executives
董事长：谭丽霞
副董事长：徐俊
董事：顾琮祺,龚鹰,王全立,徐俊,Amarant Martínez Carrió,谭丽霞
独立董事：卜祥瑞,洪瑛,贾继辉
Top 5 Shareholder
Shareholder name Nature Holding Date
海盈康（青岛）医疗科技有限公司流通A股20.02%30/09/2024
GRIFOLS,S.A.流通A股6.58%30/09/2024
中国信达资产管理股份有限公司流通A股4.21%30/09/2024
华宝信托有限责任公司－华宝－中信1号单一资金信托流通A股4.04%30/09/2024
中国中信金融资产管理股份有限公司流通A股3.71%30/09/2024
Company Secretary 刘峥
Solicitors 北京国枫律师事务所
Auditors 大华会计师事务所（特殊普通合伙）
Tel No 021-22130888-217
Fax No 021-37515869
Website www.raas-corp.com
Email raas@raas-corp.com
Company Address
Register: 上海市奉贤区望园路2009号
Office: 上海市奉贤区望园路2009号
Listing Date 23/06/2008
Shares Capital
Shares Capital: 6,637,984,837
Total A Share: 6,637,984,837
Listed A Share: 6,634,789,612
Non-tradable A Share: 3,195,225
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.270
DPS(RMB)* ¥ 0.030
NBV Per Share(RMB)* ¥ 4.459
Market Capitalization(RMB) 51.154B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.